Skip to main content

Diabetes

  • Takeda resubmits new drug applications for Type 2 diabetes treatments

    OSAKA, Japan — Japanese drug maker Takeda Pharmaceutical is reapplying for approval of two drugs to treat Type 2 diabetes after the Food and Drug Administration turned down its last applications, the company said.

    Takeda announced that it resubmitted its applications for alogliptin and a drug that combines alogliptin with pioglitazone, the active ingredient in Actos, which the FDA approved in 1999.

    The FDA will review the applications over the next six months, the drug maker said.

  • Welchol oral suspension now can be mixed with fruit juice, diet soft drinks or water

    PARSIPPANY, N.J. — The Food and Drug Administration has approved a new means of administration for a drug made by Daiichi Sankyo, the drug maker said Monday.

    Daiichi Sankyo announced the FDA approval of Welchol (colesevelam hydrochloride) for oral suspension to be mixed with fruit juice or diet soft drinks. The drug, used to improve blood-sugar control and cholesterol levels in patients with Type 2 diabetes and high cholesterol, received approval in 2009 for mixing with water.

  • Better glycemic control achieved among diabetics with authoritative parents, study finds

    ALEXANDRIA, Va. — Children with Type 1 diabetes may achieve better blood-sugar control if their parents are more authoritative with them, a new study has found.

  • American Diabetes Association introduces guide for mothers with Type 1, Type 2, gestational diabetes

    ALEXANDRIA, Va. — The American Diabetes Association has released a new guide catering to diabetic women that are planning to expand their brood and those who develop gestational diabetes during pregnancy.

  • Study finds cholesterol drug torcetrapib may help control diabetes

    NEW YORK — A drug designed to boost high-density lipoprotein cholesterol levels also may improve blood-sugar control for diabetics, according to a new analysis of a discontinued study.

    Australian researchers found that torcetrapib, a cholesteryl ester transfer protein inhibitor, could improve HDL or "good" cholesterol levels while improving blood-sugar control among diabetics.

  • Study: Metformin use during adolescence may help girls delay, prevent PCOS

    NEW YORK — A study slated to appear in the Journal of Clinical Endocrinology & Metabolism, a publication of the Endocrine Society, found that adolescent girls that take the diabetes drug metformin may prevent or delay the development of polycystic ovary syndrome, a common cause of infertility.

  • Dentists may help ID prediabetes, diabetes among undiagnosed patients

    NEW YORK — A visit to the dentist may offer a chance to catch prediabetes or diabetes in patients unaware that they have it, according to a new study.

    Researchers at Columbia University’s College of Dental Medicine found that patients seeing a dentist could be identified as showing symptoms of the conditions, such as periodontal disease.

  • FDA committee doesn't recommend regulatory approval for dapagliflozin

    WILMINGTON, Del. — A Food and Drug Administration committee of experts has advised against approving a drug for Type 2 diabetes made by AstraZeneca and Bristol-Myers Squibb, the companies said Tuesday.

    The FDA’s Endocrinologic and Metabolic Drugs Advisory Committee voted 9-6 against recommending approval for dapagliflozin, saying that data from a two-year clinical trial program that included about 6,000 people did not support the drug’s approval for use in patients along with changes to diet and exercise.

X
This ad will auto-close in 10 seconds